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Response to reviewers 
Reviewer 2 
Major Comments: 
 Page 8:  More data on ERCC2 was published in JAMA earlier this year (PubMed PMID: 
27310333) and should be included in the discussion of ERCC2.  Should be added to table 1 
also. 
We thank the Reviewer for the suggestion. We added the data about ERCC2 published by 
Liu D. et al in JAMA 2016, both in the text and in Table 1. 
 Page 8.  The ATM, RB and FANCC signature is discussed under the heading gene expression 
signatures.  This signature is a genomic DNA repair defect signature based on alterations 
determined by sequencing.  Recommend either discussing this in the DNA damage repair 
section of the manuscript or editing the subtitle to convey the nature of the signature.  
As suggested, we moved the date about ATM, RB and FANCC signature from the section 
“gene expression signature” to the section “DNA damage repair”.  
 P 10  "The combination of GDPD3 and SPRED1 resulted in a multivariate classification tree 
that was significantly associated with the chance of obtaining a response to NC." - please 
provided stats including p values to be consistent with the rest of the paper.  
We added the statistical test previously not reported (Goodman-Kruskal γ = 0.85 p<0.0001). 
 p.10 the discussion of the Williams et al Cancer research paper is not clear and somewhat 
misleading.  That paper from 2009 discusses a GEM score generated from NCI-60 cell lines 
and then validated using data obtained from human tumor tissue samples from bladder 59  
cancer patients.   
We thank the Reviewer for this comment. The sentence has been modified as follows: 
“Williams et al. validated a GEM score based on in vitro drug sensitivities and microarray 
analyses of a NCI-60 cancer cell line panel, using data obtained from human tumor tissue 
samples from 59 bladder, 143 ovarian and 275 breast cancer patients treated with 
chemotherapy. In bladder cancer patients treated with neoadjuvant methotrexate, 
vinblastine, adriamycin and cisplatin, the 3-year OS for those with favorable gene 
expression model scores was 81%, versus 33% for those with less favourable scores 
(p=0.002). 
 The bibliography may be formatted to journal specifications, but several of the references 
are abstracts and this isn't clear as they are listed (example refs 33, and 34).   
We thank the Reviewer for the remark. We checked the bibliography carefully. 
 The subtypes defined in the Choi paper are discussed on page 10-11. These signatures are 
from gene expression data, not sequencing.  Recommend expanding on the data linking 
these subtypes with chemotherapy sensitivity and resistance.  
As suggested, we highlighted that the subtypes proposed by Choi et al are from gene 
expression data and we expanded the paragraph about relationship of these subtypes with 
chemotherapy sensitivity and resistance. 
*Point-by-point Response to Reviewers
• p.15 it is not clear why the TCGA driver mutations and targeted therapies are 
highlighted in the discussion session.  These sections do not relate to the data presented 
nor to this section of the text 
We agree with the Reviewer that some topics (TCGA, targeted therapies) are currently not 
directly related to the object of our review. However, in the Discussion, we discussed some 
topics that will be probably relevant in the near future. In detail, we placed the paragraph 
about the TCGA in the Discussion, because we wanted to emphasize, among the final 
messages of the paper, that further studies of histopathological and molecular features of 
each TCGA subtype are strongly needed, to improve our understanding of mechanisms that 
underlie treatment response or resistance. Similarly, another message that we wanted to 
emphasize is the modest activity obtained in bladder cancer with most targeted therapies, 
underlying, even with these drugs, the complexity of mechanisms of resistance, and the 
need of better selecting patients.   
 P 16 Would end on a more forward-looking note rather than repeat text from the opening 
paragraph "Validate predictive biomarkers of response to NC are currently lacking for 
MIBC." Furthermore that sentence is not technically true as both ERCC2 and the ATM/RB1 
FANCC signatures were validated in independent datasets.  
We have replaced the sentence with: “Many efforts have been and are continuing to be 
made to identify and validate predictive biomarkers of response to NC.” 
 Highlights bullet points have many typos and state "Genetic and molecular features can 
help to identify patients likely to benefit from NC" - but the in the body of the text the 
authors make the point that "Validate predictive biomarkers of response to NC are 
currently lacking." 
As suggested we revised the highlights bullet point. 
 Suggest adding the Choi subtypes to Table 1, there is enrichment for response in some 
subsets vs others as described in the text 
We thank the Reviewer for the suggestion. We added the Choi sybtype to table 1. 
 
Minor comments: 
 Consider grouping discussion of micro-environment related molecules and 
targeted/immunotherapies together as future directions since there is no data related to 
neoadjuvant outcomes with these molecules/agents.  
As the reviewer suggested we grouped discussion of micro-environment related molecules 
and targeted/immunotherapies together as future directions. 
 Typo on page 7 "immunoistochemical expression of ERCC1 and PR (pT0)"  - should be pCR. 
We corrected the acronym PR.  
 P 7: GCGS - acronym not previously defined  
We corrected the acronym GC (gemcitabine and cisplatin) 
 P13 - revise for clarity "The standard of care for MIBC should combine cisplatin-based 
chemotherapy followed by radical cystectomy with extended pelvic lymph (node) 
dissection." 
We revised the sentence. 
 P 14 - Unfortunately these biomarkers cannot (yet?) be used to select patients who benefit 
from NC. 
As suggested we inserted “yet” in the sentence. 
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Molecular biomarkers to predict response to neoadjuvant 
chemotherapy for bladder cancer 
Abstract 
Cystectomy is the gold standard for treatment of localized muscle-invasive bladder cancer. 
However, about 50% of patients develop metastases within 2 years after cystectomy and 
subsequently die for the disease. Neoadjuvant cisplatin-based chemotherapy before cystectomy 
improves the overall survival in patients with muscle-invasive bladder cancer, and pathological 
response to neoadjuvant treatment (downstaging to ≤pT1 at cystectomy) is a strong predictor of 
better disease-specific survival. Nevertheless, some patients do not benefit from neoadjuvant 
therapy. The identification of reliable biomarkers that could enable the clinicians to identify 
patients who will really benefit from neoadjuvant chemotherapy is a major issue. This approach 
could lead to individualized therapy, in order to optimize the chance of response, avoiding the 
impact of neoadjuvant treatment on quality of life and the delay of cystectomy in non-responder 
patients. However, no molecular predictive biomarkers have shown clinical utility. 
This paper aims to review currently available data about biomarkers predictive of response to 
neoadjuvant chemotherapy in muscle-invasive bladder cancer. 
 
Running title 
Predictive biomarkers in bladder cancer neoadjuvant chemotherapy 
Keywords 
Bladder cancer, urothelial carcinoma, neoadjuvant chemotherapy, biomarkers, resistance, 
sensitivity. 
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Introduction 
Bladder cancer (BC) is usually diagnosed at a surgically resectable stage, and early radical 
cystectomy with pelvic node dissection remains the cornerstone of therapy of muscle-invasive 
disease. However, cancer-specific survival after cystectomy is relatively low, ranging from 72% at 5 
years for patients with organ-confined disease, to 48-25% at 5 years in patients with extravescical 
extension or lymph node metastases. Nearly half of patients diagnosed with stages T2b-T4a 
develop metastatic disease within two years [1]. 
The low cure rates with radical cystectomy imply that, in many cases, muscle-invasive bladder 
cancer (MIBC) is ab initio a micro-metastatic disease. This supports the use of perioperative 
systemic treatment, to achieve a better disease control and improve survival. In fact, the rationale 
of neoadjuvant treatment is the early eradication of micro-metastases, combined to a down-
staging of the primary tumor in patients with clinical stage T2-T4a N0 M0 MIBC, candidates for 
definitive surgery or radiation. Furthermore, neoadjuvant treatment is better tolerated than 
chemotherapy after surgery, due to the relevant post-cystectomy morbidity. Finally, using 
neoadjuvant therapy, activity of systemic treatment can be tested in vivo, obtaining important 
prognostic data. 
The literature clearly supports neoadjuvant chemotherapy (NC), demonstrating a 5-10% increase in 
5-year cancer-specific survival in MIBC compared with surgery alone. Interestingly, the 5-year 
cancer-specific survival for responders to NC (<ypT2) is 90%, in contrast to the 30-40% for those 
not obtaining an objective response. Conversely, data supporting adjuvant chemotherapy are less 
robust. Yet, despite level-one evidence [2, 3], neoadjuvant cisplatin-based chemotherapy met 
resistance in medical communities around the world [4], mainly due to the concerns related to the 
disappointing delay of surgery in non-responders patients, the potential toxicity, and the inability 
to predict the chance of response. 
However, to date, no method exists for predicting response to NC, and some patients will suffer 
from its toxicity, without achieving any benefit. Furthermore, due to a deterioration in their 
physical conditions possibly associated with the absence of activity of neoadjuvant treatment, 
some patients will lose the opportunity for additional, alternative therapy. Hence, the ability to 
identify patients who would really benefit from NC is a major clinical issue.  
The aim of this review is to summarize and discuss currently available data about biomarkers 
tested as predictive factors of response to NC in MIBC. 
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Neoadjuvant cisplatin-based chemotherapy for bladder cancer 
Two large, randomized trials [5, 6] and two meta-analyses [7, 8] showed that NC provides survival 
benefit compared with surgery alone in patients with MIBC. In the SWOG 8710 randomized trial 
[5], 317 patients with operable clinical T2-T4, N0 M0 disease were assigned to receive three cycles 
of NC with methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) followed by cystectomy, or 
cystectomy alone. The study was designed with overall survival (OS) as primary endpoint. OS was 
longer in patients assigned to chemotherapy (median 77 vs. 46 months), although this difference 
did not reach the threshold of statistical significance (p=0.06). Neoadjuvant MVAC yielded a 
significantly higher pCR rate (38% vs 15%, p<0.001), which was associated with a significant higher 
5-year survival (85%). 
In the International Collaboration of Trialists study [6] 976 patients with clinical T2 grade 3, T3 or 
T4a, node negative bladder cancer were randomized to receive 3 cycles of neoadjuvant cisplatin, 
methotrexate, and vinblastine (CMV) or no chemotherapy before local treatment (radical 
cystectomy or radiation). NC demonstrated a statistically significant 16% reduction in the risk of 
death (HR 0.84; 95% CI 0.72-0.99, p=0.037), corresponding to an increase in 10-year survival from 
30% to 36% with neoadjuvant treatment. In the subgroup of 428 patients who underwent 
cystectomy, pCR was higher in the chemotherapy arm (32 vs 12%)[9]. 
Two main meta-analyses have been performed [7, 8], both showing a significant survival benefit 
associated with NC. In the first one [7], based on individual data of 3005 patients from 11 trials, the 
5-year survival  improved from 45 to 50%, with a 14% reduction in the risk of death (HR: 0.86; 
95%CI 0.77-0.95, p=0.02) for patients assigned to NC. 
Based on this evidence, NC has been recommended by consensus guidelines in both the United 
States and Europe [2, 3]. 
In 2000, similar efficacy but improved toxicity was reported with gemcitabine and cisplatin (GC) 
compared with standard MVAC in patients with metastatic BC [10]. This experience in advanced 
disease has been extrapolated to the neoadjuvant setting; thus, 3-4 cycles of GC are frequently 
used as neoadjuvant treatment [11], although this combination has never been prospectively 
evaluated [12]. 
Two multicentre prospective trials tested modifications of the classical MVAC regimen to either 
accelerated MVAC [13] or dose-dense MVAC [14]. Both studies treated approximately 40 patients 
with 3-4 cycles of modified MVAC. In the first study [13], accelerated MVAC obtained pCR in 38% of 
patients, in the second one 49% of patients achieved a pathological response, defined by 
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pathological downstaging ≤pT1, after dose-dense MVAC [14]. These studies demonstrated that 
modified MVAC regimen considerably reduced time to surgery, with an acceptable safety profile, 
and showed that toxicity did not preclude subsequent surgery.  
Based on the available data CMV, MVAC and GC combinations can be used in the neoadjuvant 
setting. 
In summary, early eradication of micro-metastases combined to a down-staging of the primary 
tumour, and its significant impact on survival are the strengths of NC, which also provides a better 
toxicity profile, compared to adjuvant chemotherapy. Potential disadvantages of NC include less 
accurate staging, possible increased surgical morbidity and mortality, and delay in curative surgery. 
Moreover, patients with disease progression during NC will not benefit from surgery.  
Biomarkers predictive of response to neoadjuvant chemotherapy for muscle-
invasive bladder cancer. 
Multiple molecular biomarkers have been studied for prediction of response to NC, including: 
regulators of apoptosis and cell survival, pathways involved in DNA repair, receptor tyrosine 
kinases, gene expression patterns, cellular mechanisms of drug uptake and transport, 
microenvironment-related molecules (Table 1). 
 
Regulators of apoptosis and cell survival. 
p53 acts as a tumor suppressor gene, able to respond to DNA damage, inducing cell cycle arrest 
and regulating cell survival and apoptosis.  
Alterations in the p53 gene have been reported in about 50% of bladder cancers, correlated with 
high grade and advanced stage [15]. Mutant p53 protein is usually overexpressed, due to increased 
stability compared to wildtype product. In vitro, most p53 mutations confer sensitivity to cisplatin 
and doxorubicin in bladder cancer cells [16]. However, there are conflicting data about the 
relationship between chemosensitivity and p53.  
In a phase II trial testing accelerated MVAC as neoadjuvant treatment, Plimack and colleagues 
analysed molecular alterations in baseline tumour samples [13]. No correlation was demonstrated 
between p53 deleterious mutations and response to chemotherapy[13]. A further study reported 
that p53 immunoreactivity did not predict response to preoperative systemic chemotherapy in 
patients with invasive urothelial carcinoma [17]. 
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Several studies in patients undergoing NC MVAC demonstrated a correlation between p53 
overexpression at immunohistochemistry and poor outcome [18-20]. On the contrary, Watanabe 
et al. [21] demonstrated that wild-type p53, investigated with cDNA sequencing, was related to a 
poor response to systemic chemotherapy in a series of surgically treated urothelial tumor 
specimens.  
The proteins of Bcl-2 family are implicated in the response of cells to apoptotic stimuli.  
Bcl-2 is an anti-apoptotic protein, that has been shown as a predictive marker to either 
chemotherapy or radiotherapy in advanced bladder cancer [22, 23].  
Cooke and collaborators randomized 51 patients with MIBC to radiotherapy or radiotherapy plus 
neoadjuvant cisplatin. The study did not demonstrate a prognostic role of Bcl-2 positivity in the 
overall study population but, when only the subgroup of patients who received cisplatin [24] was 
considered, Bcl-2 negative patients had a median survival of 72 months compared with 17 months 
of Bcl-2 positive patients (p<0.03); the 5-year survival rate was respectively 55% and 14%. Authors 
suggested that the determination of Bcl-2 status in patients undergoing radiotherapy for MIBC 
could help to identify those who may benefit from neoadjuvant chemotherapy. 
 
Pathways involved in DNA repair. 
The breast cancer susceptibility gene 1 (BRCA1) codifies for a nuclear protein, involved in biological 
processes related to response to therapeutic DNA damage. Low BRCA1 levels are associated with 
sensitivity to cisplatin [25]. In order to investigate the predictive role of BRCA1 mRNA expression in 
BC, tumor samples of 57 bladder cancer patients treated with NC (CMV or gemcitabine and 
cisplatin) were retrospectively analysed using quantitative polymerase chain reaction [26]. Patients 
were divided into terciles according to BRCA1 levels. Sixty-six percent of patients with 
low/intermediate BRCA1 levels attained a PR, defined as pT0-T1, compared to 22% of those with 
high levels. Furthermore, median survival was longer in patients with low BRCA1 expression (168 
versus 34 months, p=0.002). In multivariate analysis, only lympho-vascular invasion  and BRCA1 
mRNA expression levels (HR: 2.73, 95%CI: 1.16-6.39, p=0.02) emerged as independent prognostic 
factors of overall survival. However, these results have not been validated in an external series .  
Other genes involved in DNA repair (ERCC1 and RRM1) or in drug resistance (MDR1 and caveolin-1) 
have been assessed as potential predictive or prognostic markers in the adjuvant or metastatic 
setting, suggesting a possible role for MDR1 and ERCC1 [27, 28]. 
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The cytotoxic effect of platinum-based chemotherapy has been attributed to the formation of 
bulky platinum DNA adducts. Cisplatin resistance seems to be associated with the removal of these 
DNA adducts by the nucleotide excision repair (NER) system, a highly conserved DNA repair 
system. Excision repair cross complementing 1 (ERCC1) is the lead enzyme in NER process, and its 
role as a predictor of platinum sensitivity was initially highlighted in a study of patients with 
radically resected non-small-cell lung cancer treated with cisplatin-based adjuvant chemotherapy 
[29]. ERCC1-negative tumors seemed to benefit from cisplatin-based chemotherapy, whereas 
patients with ERCC1-positive tumors did not. In bladder cancer, in the trial testing dose-dense 
MVAC NC, Choueiri et al. [14] tested, as secondary endpoint, the relationship between 
immunoistochemical expression of ERCC1 and pCR (pT0). Of the 31 patients enrolled in the study 
with adequate pre-treatment tumor specimens, 12 patients (39%) were classified as ERCC1 
positive. With the clear limitation of the small sample size, no significant association between 
ERCC1 positivity and pCR was detected. In detail, 43% of ERCC1-positive and 60% of ERCC1-
negative patients achieved pCR. 
Conversely, in a retrospective study, low levels of ERCC1 mRNA, determined by RT-PCR in tumor 
DNA from 57 advanced and metastatic bladder cancer patients treated with either GC or 
gemcitabine, cisplatin and paclitaxel, were associated with a significantly longer survival (median 
24.5 versus 15.4 months; p=0.03) and longer time to disease progression, although the difference 
in the latter endpoint did not reach statistical significance [27]. On multivariate analyses with pre-
treatment prognostic factors, ERCC1 emerged as an independent predictive factor of survival. A 
longer time to progression, although not statistically significant, was also observed in patients with 
low levels of ribonucleotide reductase subunit M1 (RRM1), BRCA1 and caveolin-1. However, a clear 
link between the expression of these four markers and response to chemotherapy has not been 
established. 
ERCC2, a nucleotide excision repair gene, is another leading actor in the NER system. In a 
retrospective study [30], the authors performed whole exome sequencing on pre-treatment tumor 
from 50 patients with muscle invasive urothelial carcinoma who received neoadjuvant cisplatin-
based chemotherapy. Comparing the profile of cisplatin responders (T0/Tis) with non-responders 
(≥pT2), ERCC2 was the only mutated gene significantly enriched in the cisplatin responders. While 
ERCC2 mutations occur in approximately 12% of unselected cases, 36% of responders harboured 
somatic, non synonymous mutations of ERCC2. Moreover, all ERCC2 mutant tumors responded to 
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NC, suggesting that ERCC2 mutations result in loss of normal ERCC2 function, leading to increased 
tumor cell sensitivity to DNA-damaging agents such as cisplatin. 
A subsequent study confirmed that ERCC2 missense mutations were more common in NC 
complete responders to cisplatin-based NC, but this association did not reach statistical 
significance: 6 somatic ERCC2 missense mutation were identified in 38 complete responders (16%) 
and 2 in 33 non-responders (6%; p=0.27) [31]. 
In a more recent study Liu et al. [32] investigated the association of ERCC2 somatic mutations and 
pathological response to cisplatin-based NC in 62 patients with MIBC from 2 clinical trial of NC who 
completed 3 cycles of chemotherapy. Among 48 patients included in the analysis 40% of 
responders and 7% of non-responders had a non-synonimous ERCC2 genetic alteration (odds ratio: 
8.3; 95% CI: 1.4-91.4; p=0.01). There was a statistically significant difference in OS among patients 
with compared to those without ERCC2 alterations (p=0.03).  
Recently, Iyer et al. investigated the relationship between alterations in a DNA damage repair 
(DDR) gene set and response to NC in 46 patients enrolled in a phase II study [33] of neoadjuvant 
dose-dense GC. The most frequently altered DDR genes were BRCA2 and ATR (12% each). The 
median number of DDR alterations in responders vs non-responders was similar (1 vs 2); however, 
5 of 14 responders had deleterious DDR alterations vs 0 of 10 non-responders (p=0.053).[34] 
In a prospective study [35], Plimack et al. demonstrated that genomic alterations in DNA repair-
associated genes ATM, RB and FANCC predict response and clinical benefit after cisplatin-based NC 
for MIBC, confirming that defective DNA repair can increase tumour sensitivity to cisplatin. DNA 
obtained from a discovery set of prospectively collected pre-treatment tumour samples from 
patients treated in the trial testing accelerated MVAC [13], was sequenced for all coding exons of 
287 cancer-related genes and was analysed for base substitutions, copy number alterations and 
selected rearrangements. A set of identically collected samples from a follow-up trial of similar 
design testing 3 cycles of neoadjuvant dose-dense GC chemotherapy [36] was used as validation 
cohort. Patients with pCR had more alterations than those with residual tumor in both the 
discovery (p=0.024) and validation (p=0.018) cohort. In the discovery set, alterations in ATM, RB1 
or FANCC predict pathologic response (p<0.001, 87% sensitivity, 100% specificity) and better OS 
(p=0.007) (Table 1). 
 
Receptor tyrosine kinases. 
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ERBB2 is an orphan receptor, member of the epidermal growth factor receptor family, without a 
known, specific ligand. ERBB2 is over-expressed in many tumors, and showed to correlate with 
tumor recurrence and metastases development in BC [37].  
In a recent study, 9 of 38 complete responders (ypT0N0) to cisplatin-based NC had ERBB2 missense 
mutations, whereas none of 33 non-responders (higher than ypT2) had ERBB2 mutations (p=0.003) 
[31]. 
 
Gene expression signatures: gene expression models predictive of response to NC. 
Profiling of gene expression patterns on genome-wide cDNA microarrays is another useful 
approach to identify molecules related to response to anticancer drugs. 
Takata et al. analysed biopsy materials from 18 transitional cell BC patients using a cDNA 
microarray including 27648 genes. Patients who achieved pathological (≤pT1) or radiological (≤cT1) 
downstaging after 2 cycles of MVAC NC, were classified as responders. Fourteen genes separated 
the responders from non-responders and allowed the determination of a numerical prediction 
scoring system [38]. Among those genes, topoisomerase 2a, a target of doxorubicin, was 
downregulated in non-responders. Subsequently, the investigators externally validated these 
findings in a small dataset [39]. This scoring system correctly predicted response for 8 out of 9 test 
cases in the first report [38], and for 19 out of 22 test cases in the second report [39]. However, 
these analyses are limited by the modality of response assessment (imaging only at least in some 
patients) and obviously by the small number of patients. 
Kato and colleagues [40] analysed gene expression profiles in biopsy samples from 37 patients with 
advanced BC, using a microarray of 38500 genes, to establish a method for predicting response to 
NC with carboplatin and gemcitabine. They found 12 genes significantly differentially expressed 
between responders and non-responders, and established a numerical prediction scoring system 
clearly separating the two groups. Among those 12 predictive genes, IPO7, encoding for a protein 
that imports proteins into the nucleus acting as an adapter-like protein, was up-regulated in the 
non-responders and probably contribute to resistance through inhibiting caspase-3 activity, as 
previously described in ovarian cancer cells [41, 42]. Furthermore, solute-carrier family 22, 
member 18 (SLC22A18), encoding for an organic cation transporter, that belongs to the 
polyspecific transporter/multi-drug resistance gene family, was up-regulated in non-responders. 
Pharmacogenomic studies suggest that SLC22A18 could be a transporter of gemcitabine [43]. 
Hence, SLC22A18 up-regulated expression may contribute to resistance to gemcitabine. 
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Messenger-RNA expression data from the report of Kato and colleagues were subsequently re-
analyzed in conjunction with the antibody dataset of the Human Protein Atlas, in order to identify 
candidate protein biomarkers detectable by immunohistochemistry [44]. The authors identified 8 
candidate protein biomarkers, that were tested in tissue microarrays derived from baseline 
biopsies of 37 patients, subsequently treated with CG NC and cystectomy. 
The combination of GDPD3 and SPRED1 resulted in a multivariate classification tree that was 
significantly associated with the chance of obtaining a response to NC (Goodman-Kruskal γ = 0.85 
p<0.0001). Also clinical factors, such as age > 60 at cystectomy and clinical stage > cT2, were 
independent factors significantly associated with NC resistance. The authors proposed two 
independent models, the first based on clinical factors and the second based on protein markers, 
and both models were strongly associated with the prediction of resistance to NC. Finally, the 
combination of the two models resulted in a prediction model able to significantly stratify the 
likelihood of NC resistance in the tested cohort (n=37) into two well separated groups (p=0.0002): 
low (26%, n=19) and high (89%, n=18). 
All these gene expression models are developed using a training microarray set from tumors of 
patients with known clinical responses. Although validation is straightforward, it can be long and 
expensive, requiring human tumor tissue from patients treated with the specific drug regimen 
used in patients included in the training set. Moreover, this approach does not permit prediction of 
responses to drugs not used in the model development. To overcome these limitations, Williams et 
al. [45] validated a GEM score based on in vitro drug sensitivities and microarray analyses of a NCI-
60 cancer cell line panel, using data obtained from human tumor tissue samples from 59 bladder, 
143 ovarian and 275 breast cancer patients treated with chemotherapy [46-48]. In bladder cancer 
patients treated with neoadjuvant methotrexate, vinblastine, adriamycin and cisplatin, the 3-year 
OS for those with favorable gene expression model scores was 81%, versus 33% for those with less 
favourable scores (p=0.002). Studies developing gene expression models predictive of response to 
NC are shown in Table 1. 
In 2014, the South-west Oncology Group (SWOG) launched a neoadjuvant trial (NCT02177695), 
currently recruiting, in MIBC patients, to compare the efficacy of the two frontline chemotherapy 
regimens (GC versus MVAC) and the ability of a gene expression profiling-based algorithm, called 
CoXEN, to predict cPR [49]. 
 
Molecular subtypes of bladder cancer: emerging targets and biomarkers of treatment. 
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Recent studies integrating genomic data from gene expression array, targeted mutation sequencing 
analyses and protein analyses, defined clinically relevant molecular subtypes of bladder cancer. 
Lindgren et al. [50] first recognized the worse prognosis associated with a gene expression profile 
of a keratinized/squamous phenotype. This molecular subtype, termed “basal like”, and 
characterized by p63 activation, squamous differentiation, positive CK5/6, EGFR, and cluster of 
differentiation (CD)44 expression and lack of cytokeratin (CK)20, was further validated by Choi [51], 
who used whole genome mRNA expression profiling to identify 3 distinct subtypes of MIBC: “basal 
like”, “luminal like” and “p53-like”. Basal tumors were characterized by squamous differentiation 
and were associated with shorter disease-specific and overall survival, but responded to NC, as do 
some basal breast cancers. Hence, early management of “basal like” MIBCs with NC could offer to 
these patients the best chance for improved survival for patients with this potentially deadly form 
of disease. Luminal subtype” were characterized by active PPARɣ and estrogen receptor (ER) 
transcription and enriched with activating FGFR3 mutations. Therefore, the authors suggested that 
agents targeting ER, ERBB2/3, PPARɣ or FGFR, may be clinically active in this subtype of MIBC. Since 
several “luminal” MIBC responded to NC, these targeted therapies should probably be tested in 
combination with conventional chemotherapy. “P53-like” MIBC subtype  is characterized by wild-
type TP53 expression. The authors observed that all of the p53-like MIBCs from patients treated 
with NC in the discovery cohort (n = 7) were resistant to chemotherapy. To further probe this 
relationship, they explored the chemo resistance of p53-like MIBCs in an expanded NC cohort (n = 
34) and in an additional cohort of 23 archival tumors of patients treated with MVAC in a phase III 
trial. They found that p53-like MIBCs in both cohorts were resistant to NC. They finally 
demonstrated that, upon resistance to chemotherapy, tumors originally classified as “basal-like” 
and “luminal” subtypes also shifted to a “p53-like” phenotype.  
 
Cellular mechanisms of drug uptake and transport. 
Copper transporter receptor 1 (CTR1) plays an important role in platinum uptake, and a recent 
study demonstrated a correlation between CTR1 tumor expression and pathological outcome in 47 
MIBC patients treated with neoadjuvant cisplatin-based chemotherapy (p=0.0076 in pre-treatment 
specimens and p=0.023 in post-treatment specimens) [52].  
Reports on P-glycoprotein [53] in tumor specimens of metastatic urothelial carcinoma suggested 
that this factor might predict resistance to chemotherapy and risk of treatment toxicity. P-
glycoprotein expression (the product of the multidrug resistance gene, MDR-1) has been studied in 
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pre- and post-chemotherapy fresh frozen tissue sections of primary and metastatic urothelial 
tumours of patients treated with MVAC showing an increase in the proportion of cells expressing P-
glycoprotein after exposure to chemotherapy [53]. The role of P-glycoprotein has never been 
specifically investigated in neoadjuvant setting. 
Future directions 
Also the role of microenvironment-related molecules has been studied in urothelial BC, to define 
their potential impact on cisplatin resistance. Afonso et al. [54] investigated the clinical-
pathological and prognostic significance of the monocarboxylate transporters (MCT) 1, MCT4, 
CD147, CD44 and carbonic anhydrase IX (CAIX) in a cohort of 114 patients with urothelial BC who 
underwent transurethral resection and/or cystectomy. The presence of MTC1, MTC4 and/or CD147 
was associated with unfavourable prognosis. Moreover, when selecting patients who received 
cisplatin, prognosis was significantly worse in those with MTC1 and CD147 positive tumors. CD147 
specific silencing by small interfering RNAs (siRNA) in urothelial bladder cancer cells resulted in an 
increase in chemosensitivity to cisplatin. Similar results were obtained in advanced bladder cancer, 
where CD147 expression was related to response to cisplatin-containig regimens [55]. 
Elevation of glutathione, a tripeptide that conjugates with many electrophiles (including some 
cytotoxic agents), has been widely demonstrated in cells resistant to platinum complexes and 
alkylating agents [56]. In vitro higher level of glutathione were found in transitional cell carcinoma 
compared to tumor-free bladder tissue and in nontumor bladder tissue from patients with bladder 
cancer than from patients without transitional cell carcinoma [57].  
Siu et al. investigated the prognostic role of metallothionein in tissue from primary tumors of 118 
patients with urothelial cancer subsequently treated with cisplatin-based chemotherapy. 
Overexpression of metallothionein was associated with poorer outcome, possibly due to cisplatin 
resistance [58]. However, the impact of glutathione and metalloproteinase expression has never 
been studied in patients treated with NC. 
Finally, several clinical trials testing targeted therapies and immunotherapies in the neoadjuvant 
setting for MIBC have been performed.  
Two studies tested bevacizumab in combination with chemotherapy (GC and dose-dense MVAC), 
showing a pathologic response rate  of 31 and 53% respectively [59, 60]. Two studies that 
investigated sunitinib with chemotherapy in neoadjuvant setting were stopped early due to toxicity 
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[61, 62]. Other two studies tested the efficacy of tyrosine kinase inhibitors, erlotinib [63] and 
dasatinib [64], reporting pathological response rates of 35 and 14% respectively. 
A phase II trial of Lapatinib in association to GC as neoadjuvant therapy in MIBC, was terminated 
early due to toxicity [65]. 
To date, however, there are no biomarkers predictive of response to targeted therapies, neither in 
the neoadjuvant setting nor in the advanced disease.  
A phase 1-2 trial is currently testing the combination of chemotherapy (GC) with ALT-801, an 
innovative immunotherapeutic fusion protein consisting of interleukin-2 (IL-2), linked to a single 
chain T cell receptor domain (scTCR), developed to target cancer cells that overexpress the tumor-
associated antigen p53, in neoadjuvant setting (NTC01326871). 
A small study investigated the immunologic effects of Ipilimumab in 12 patients with localized 
bladder urothelial carcinoma before surgery. All patients had an increased frequency of 
CD4+ICOShi T cells in the systemic circulation and tumor tissues, that has been shown to correlate 
with OS improvement in melanoma [66]. 
Another ongoing trial evaluates neoadjuvant pembrolizumab in combination with GC in patients 
with T2-4a N0 M0 urothelial cancer (NCT02365766). 
In addition, immunotherapy is under study in the neoadjuvant setting within a phase II study with 
atezolizumab, an anti-PD-L1 antibody, administered to subjects with either BCG-refractory non-
MIBC, or MIBC appropriate for cystectomy and refusing or ineligible for neoadjuvant 
chemotherapy (NCT02451423).  
If immunotherapy would be confirmed to be effective in neoadjuvant setting, it will require the 
identification of biomarkers predictive of response. In the phase II trial testing atezolizumab in 310 
patients with locally advanced and metastatic urothelial carcinoma after treatment with platinum-
based chemotherapy, the percentage of PD-L1 positive immune cell (IC0 <1%; IC1 ≥1% but <5%; 
IC2/3 ≥5%) was related to objective response rate (ORR). ORRs were 26%  in the IC2/3 group, 18%  
in the IC1/2/3 group and 15% in all 310 patients. Moreover a link between response to atezolizumab 
and intrinsic molecular subtypes of bladder cancer according to The Cancer Genome Atlas (TCGA) 
classification was described. Response to atezolizumab occurred in all TCGA subtypes, but was 
significantly higher in the luminal cluster II subtype (ORR 34%) compared to other subtypes (10% 
for subtype I, 16% for subtype III and 20% for subtype IV) [67]. 
Clinical trials testing targeted therapies and immune checkpoints inhibitors in neoadjuvant setting 
are shown in Table 2. 
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Discussion 
The standard of care for MIBC should combine cisplatin-based chemotherapy followed by radical 
cystectomy with extended pelvic lymph node dissection. Complete PR is the most important 
favourable prognostic factor correlating with better outcome after surgery; it can be easily 
determined after cystectomy following 3-4 cycles of NC [68]. Unfortunately, only approximately a 
third of patients achieve such a response [5]. Therefore the identification of predictive factors of 
response is an urgent unmet need, to avoid chemotherapy toxicity and surgery delay in non 
responders. Few existing clinical-pathological tools have been used to identify patients at high risk 
of progression that could benefit from NC. Culp et al. developed a risk stratification model 
according to the presence of cT3b-T4a disease, hydroureteronephrosis and/or histological 
evidence of lymphovascular invasion, neuroendocrine or micropapillary features. High risk patients 
showed lower 5-year OS (47.0% vs 64.8%) and lower disease specific (64.3% vs 83.5%) and 
progression-free (62.0% vs 84.1%) survival (p <0.001) [69]. 
NC treated MIBC patients represent an ideal research setting to study resistance mechanisms and 
treatment response and to identify biomarkers predictive of response. Residual tumors after NC 
indeed may provide a valuable resource to compare with pre-treatment tumor tissue in order to 
analyse morphological and molecular features of resistant and responsive cellular clones. 
Defects in repair of DNA damage induced by treatment represent an important mechanism of 
cytotoxic chemotherapy sensitivity. In particular cisplatin, the cornerstone of NC, is an alkylating 
agent able to cause DNA fragmentation, to induce mutations in nucleotides and to inhibit DNA 
synthesis via DNA cross-linking. Several studies support the role of some DNA-repair genes, such as 
BRCA1, ERCC1, ATM, RB1, FANCC and RRM1, as biomarkers of NC sensitivity [25-29, 35].  
These studies showed a better response in patients with an higher number of alterations in DNA-
repair genes [30, 35], probably due to DNA damage accumulation. 
Furthermore some retrospective studies suggested that alterations in ERCC2 enhance cisplatin 
sensitivity [30, 31] and ERBB2 missense mutations seem to be more frequent in patients 
responding to NC [31]. 
Considering these data, DNA-repair genes mutations and missense mutations of ERCC2 and 
ERBB2/NEU pathway may be considered potential predictive biomarkers of response to cisplatin-
based chemotherapy. Unfortunately these biomarkers cannot yet be used to select patients who 
benefit from NC. All the studies testing the role of these factors as markers of treatment response 
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have  important limitations as the small number of patients and the heterogeneity of 
chemotherapy regimens.  
These candidate biomarkers require future validation in large prospective studies comparing NC 
treated patients with patients receiving only surgery to better understand if they have a role as 
predictive factors or only prognostic. 
NC has a unique strength. The comparison between pretreatment transurethral resection of 
bladder tumor (TURB) specimen and residual neoplastic tissue allows to study pathological and 
molecular characteristics of treatment-resistant cellular clones, in order to identify pathways 
responsible of treatment resistance. These pathways can be potential targets for new agents.  
Several studies have examined the prognostic significance of alterations in p53 and other cell-cycle 
regulatory proteins in bladder cancer [15]. Even though there are conflicting reports about the link 
between p53 status and chemo-sensitivity, some authors suggested that altered expression of p53 
may be associated to chemotherapy resistance [13, 17-19].  
Recent studies have shown the potential of multivariated gene expression models, developed using 
in vitro-based approach [45] or using microarray sets from tumors of human patients [39, 40], to 
predict  tumor response to chemotherapy. 
Although these intriguing results suggest that genetic features can be used to select patients 
responding to NC, these data have not yet translated into clinically predictive models useful to 
personalise bladder cancer therapy. 
Recently the TGCA Research Network completed a genomic characterization of 131 MIBC founding 
recurrent “driver” mutations in 32 genes involved in kinase signalling pathways, chromatin and 
cell-cycle regulation [70]. These data were updated in 2015 [71] and allowed the identification of 4 
main molecular clusters. 
Likewise, other studies identified 3 clinically relevant molecular subtypes associated with different 
patients outcome and with different sensitivity to cytotoxic chemotherapy [50, 51].  
The study of histopathological and molecular features of each subtype will provide in the future 
important information on mechanisms that underlie treatment response or resistance.  
Alteration in tyrosine kinase receptors, intracellular signalling pathways, such as the 
PI3K/AKT/mTOR pathway [72, 73], cell-cycle regulators, chromatin remodelling, and immune 
mediator [74], are significant in disease progression in bladder cancer, [75] and therapies targeting 
many of these alterations are currently under study. The majority of these agents demonstrated, 
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however, only modest activity [76]. This could be due to the complexity of the molecular signalling 
pathway implicated in bladder cancer and to the need of better selecting patients. 
Among receptor tyrosine kinase-targeted therapies, small molecule pan-FGFR inhibitors, have 
demonstrated encouraging results in bladder cancer patients harbouring activating FGFR mutations 
or translocations [77]. In patients with ERBB2 overexpression, preclinical results with trastuzumab 
conjugated with DM1 (derivate of maytansine 1) (T-DM1), are promising [78]. 
Others trials are currently ongoing to study the efficacy of inhibitors of cell-cycle regulators, such 
as Aurora kinase [79] and CDK4 [80] in combination with chemotherapy, and mTOR pathway 
inhibitors in combination with MEK inhibitors. 
Finally, considering the recent significant results of immunotherapy in bladder cancer, new 
treatment endpoints can be useful in this setting [67]. The anticancer immune response is a 
complex process that we can easily investigate in neoadjuvant setting in order to identify 
innovative predictive factors of response to immunological drugs. 
In conclusion cisplatin-based NC before cystectomy is the standard of care for MIBC, with 25-50% 
of patients expected to achieve a PR. Despite intriguing evidence suggesting that genetic and 
molecular characteristics can allow to identify patients likely to benefit from NC, these data have 
not yet translated into clinically useful tools.  Many efforts have been and are continuing to be 
made to identify and validate predictive biomarkers of response to NC. 
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Table 1. Biomarkers and gene expression models predictive of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer 
 
Biomarkers predictive of response to NC 
Biomarkers 
Author, year 
(ref) 
Setting Chemotherapy Patients (N) Methods Main results 
P53 
Plimack, 
2014 [13]  
cT2-T4a and N0-
N1 MIBC 
Accelerated MVAC 39 
DNA 
sequencing 
(Illumina) 
No correlation between altered p53 and response to 
NC 
Qureshi, 
1999 [17]  
Non-metastatic 
MIBC 
CM or CME or CMV 
or MVAC 
 
83 IHC 
No correlation between P53 immunopositivity and 
response to NC 
Watanabe, 
2004 [21]  
Non-metastatic 
MIBC 
CME or CMA 13 
FASAY, IHC,  
and 
sequencing 
analysis 
Six (85.7%) of 7 responders to NC harbored p53 
missense mutations in at least one allele (p=0.01) 
Kakehi, 1998 
[18]  
Non-metastatic 
MIBC 
MVAC or CME or 
CMA or  
32 IHC 
The responsiveness to NC  was correlated with p53-
negative staining status (p=0.0225) 
Sarkis, 1995 
[19]  
Non-metastatic 
MIBC 
MVAC 111 IHC 
p53 overexpression had independent significance for 
survival (p =0 .001; relative risk ratio, 3.1) 
Bcl-2 
Duggan, 
2000 [22]  
T2-T4 NXM0 
TCC of the 
bladder 
Cisplatin 100 
mg/mq every 3 
weeks 
51 IHC 
BCL-2 negative patients receiving NC had a better 
prognosis, median survival: 72 vs 17 months 
BRCA1 
Font ,2011  
[26] 
Non-metastatic 
MIBC 
CMV or GC 57 PCR 
60% of patients with low/intermediate BRCA1 levels 
atteined PR (T0-T1) vs 22% of those with high levels 
ERCC1 
Choueri, 
2014 [14] 
Non-metastatic 
MIBC 
Dose-dense MVAC 31 IHC 
43% of ERCC1-positive and 60% of ERCC1-negative 
patients achieved complete PR 
ERCC2 
Van Allen, 
2014 [30] 
Non-metastatic 
MIBC 
GC or dose-dense 
MVAC or dose-
dense GC or GC 
and sunitinib 
50 (25 
responders 
and 25 non-
responders 
Whole exome 
sequencing 
ERCC2  was the only significantly mutated gene 
enriched in the cisplatin responders compared with 
non-responders (p < 0.01) 
Liu, 2016 
[32] 
Non-metastatic 
MIBC 
Platinum-based 62 
 Whole exome 
sequencing 
Nonsynonymous ERCC2 mutations were identified in 
7% of non-responders and in 40% of responders odds 
ratio: 8.3; 95% CI: 1.4-91.4; p=0.01). 
Groenendijk, Non-metastatic MVAC or GC or 71 (38 NGS of 178 ERCC2 missense mutations were more common in 
Table 1
2016 [31]  MIBC gemcitabine-
carboplatin 
responders 
and 33 non-
responders 
cancer-
associated 
genes 
patients atteined complete PR, but not reaching 
statistical significance 
ERBB2 
9 of 38 complete responders vs 0 of 33 non-
responders had ERBB2 missense mutations ( p=0.003) 
ATM, RB and 
FANCC 
Plimack, 
2015 [35]  
Non-metastatic 
MIBC 
Discovery cohort: 
accelerated MVAC 
Validation cohort: 
dose-dense GC 
Discovery 
cohort: 34 
Validation 
cohort: 24 
Sequencing of 
287 cancer-
related genes 
ATM,RB1 and FANCC alterations were related to PR in 
both the discovery (p < 0.001) and validation set 
(p = 0.033) 
MCT1 and 
CD147 
Afonso, 2015 
[54]  
Non-metastatic 
MIBC 
Platinum-based 
chemotherapy 
31 IHC 
Prognosis was worse in patients with MCT1 or CD147 
positive tumors; OS: 42.2 vs 12.4 months (p=0.026) 
CTR-1 
Kilari, 2016 
[52]  
MIBC Platinum-based 47 IHC 
Higher CTR-1 expression score correlated  with 
pathologicalresponse (both in pre-NC specimens: 
p=0.0076 and in post NC specimens, p=0.023) 
Molecular 
subtypes: 
basal-like, 
luminal-like 
and  p53-like 
Choi, 2014 
[51] 
MIBC Platinum-based 73 
Whole 
genome 
mRNA 
expression 
profiling 
Response to NC was 0% in p53-like, 40% in basal-like 
and 67% in luminal-like subtype (p=0.018). 
Gene expression models predictive of response to NC 
GEM  Author, year Setting Chemotherapy Patients Methods Mainresults 
Numerical 
prediction 
scoring 
system 
including 14 
genes 
Takata, 2005 
[38]  
TCC bladder 
cancer 
MVAC 
18 (9 
responders 
and 9 non-
responders) 
Genome-wide 
expression 
profiling using 
a microarray 
including 
27648 genes 
14 gene separated the responders from non-
responder group. Among these genes Topoisomerase 
2, was downregulated in non-responder group. The 
scoring system correctly identified response for 8 of 9 
cases 
Takata, 2007 
[39]  
TCC bladder 
cancer 
MVAC 22 
The scoring system correctly identified response for 
19 of 22 cases 
Numerical 
prediction 
scoring 
system 
including 12 
genes 
Kato, 2011 
[40]  
T2a-T4a N0 M0 
TCC bladder 
cancer 
Carboplatin and 
gemcitabine 
Discovery 
cohort: 18 (9 
responders 
and 9 non-
responders) 
Validation 
cohort: 19 
Genome-wide 
expression 
profiling using 
a microarray 
including 
28500 genes 
12 genes separated responders  (9 patients) from 
non-responders (9 patients). Among these genes IPO-
7 and SLC22A18 were up-regulated in non-
responders.  The scoring system correctly identified 
response for 18 of 19 cases in the validation cohort 
Protein 
based 
predictive 
model 
Baras, 2015 
[44]  
T2a-T4a N0 M0 
TCC bladder 
cancer 
Carboplatin and 
gemcitabine 
37 IHC 
The combination of GDPD3 and SPRED1 resulted in a 
multivariate classification tree that was significantly 
associated with NC response (p<0.0001) 
In vitro-
based GEM 
Williams, 
2009 [45]  
Non-metastatic 
MIBC 
MVAC 59 
In vitro drug 
sensitivities 
evaluation and 
microarray 
analyses 
The 3-years OS for patients with favourable gene 
expression model score was 81% vs 33% for those 
with un-favourable score (p=0.002) 
 
MIBC: muscle-invasive bladder cancer; NC: neoadjuvant chemotherapy; MVAC: methotrexate, vinblastine, adriamycin and cisplatin ; CM: cisplatin and 
methotrexate; CMV: cisplatin, methotrexate, and vinblastine; CME: Cisplatin, methotrexate, and epirubicin; CMA: cisplatin, methotrexate and adriamycin; IHC: 
immunohistochemistry;  FASAY: yeast functional assay; TCC: transitional cell carcinoma; GC: gemcitabine and cisplatin; PR: pathological response; NGS: next-
generation sequencing; GEM: gene expression model; OS: overall survival. 
 
Table 2: Clinical trials of targeted agents or immune checkpoints inhibitors in neoadjuvant setting for urothelial cancer 
 
Reported trials 
Author , year (ref) Phase Agent Target AssociatedChemotherapy Patients (N) Outcome 
Balar, 2012 [62] II Sunitinib 
VEGFR type 1-2, PDGFR-
α-β, KIT, RET, FLT3, 
CSF1R 
Gemcitabine and cisplatin 18 PR rate: 33% 
Galsky, 2013 [61]  II Sunitinib 
VEGFR type 1-2, PDGFR-
α-β, KIT, RET, FLT3, 
CSF1R 
Gemcitabine and cisplatin 9 PR rate: 22% 
Chaudhary, 2011 
[59]  
II Bevacizumab VEGF Gemcitabine and cisplatin 15 PR rate: 31% 
Siefker-Radtke, 
2012 [60]  
II Bevacizumab VEGF Dose-dense MVAC 15 PR rate: 53% 
Narayan, 2015 [65]  II Lapatinib EGFR-ERBB2 Gemcitabine and cisplatin 6 PR rate: 17% 
Pruthi, 2010 [63]  II Erlotinib EGFR None 20 PR rate: 35% 
Hahn, 2012 [64]  II Dasatinib 
Src family tyrosine 
kinase and BCR-ABL 
None 25 PR rate: 14% 
Carthon, 2010 [66]  I/II Ipilimumab CTLA-4 None 12 
Correlation between OS and 
increase in CD4+ICOS+ T 
cells 
Ongoing trials 
Clinicaltrials.gov ID Phase Agent Target Associatedchemotherapy State  
NCT01326871 I/II ALT-801 p53 Gemcitabine and cisplatin 
Active, not 
recruiting 
 
Table 2
  
 
NCT02365766 I/II Pembrolizumab PD-1 Gemcitabine and cisplatin 
Active, not 
recruiting 
 
NCT02451423 II MPDL3280A PD-L1  None 
Active, not 
recruiting 
 
NCT02845323 II 
Nivolumab+/-
Urelumab 
CD137 receptor None 
Not yet 
recruiting 
 
NCT02812420 I/II 
Durvalumab + 
Tremelimumab 
PD-L1, CTLA-4 None 
Not yet 
recruiting 
 
NCT00749892 II Erlotinib EGFR None 
Active, not 
recruiting 
 
Highlights 
 Neoadjuvant chemotherapy (NC)  prolongs OS in muscle-invasive bladder cancer (MIBC) 
 Only a third of patients achieve pathological response to NC  
 Multiple molecular biomarkers have been studied for prediction of response to NC 
 Many efforts have been and are continuing to be made to validate predictive biomarkers of 
response to NC 
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